Alvotech
Alvotech SA is an Icelandic biopharmaceutical company focused on the development and manufacturing of biosimilar medicines for global markets. The company develops and manufactures biosimilar monoclonal antibodies targeting autoimmune conditions, inflammatory diseases, and eye disorders, including biosimilars for Humira and Stelara. Principal revenue is derived from commercial sales of biosimilar products, development milestone payments, and commercial license partnerships. Core end markets encompass hospital procurement networks, specialty pharmacies, and prescription patients in North America, Europe, and Asia-Pacific. Alvotech holds an established pioneer position in the global biopharmaceutical sector as a dedicated, fully integrated biosimilar manufacturer. The company is incorporated in Luxembourg, headquartered in Reykjavik, Iceland, and its ordinary shares trade on the Nasdaq Stock Market and Nasdaq Iceland.
2 of the funds FundTelligence covers report a position in Alvotech.
- Legal name
- ALVOTECH SA
- Sector
- Health Care
- Country
- Iceland
- Funds holding it
- 2
Funds holding Alvotech
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Lannebo Marknad Sverige Bred — Lannebo · 0.0 % (full portfolio disclosed, June 2026)